{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:22:18Z","timestamp":1783117338805,"version":"3.54.6"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>High-risk neuroblastoma (HR-NB) remains a therapeutic challenge in low- and middle-income countries. We retrospectively analyzed the clinical characteristics, treatment response, transplant outcomes, event-free survival, and overall survival of pediatric patients with HR-NB treated with intensive multimodality therapy, including autologous stem cell transplant (ASCT) at a resource-limited tertiary cancer center between January 2013 and January 2024. Children aged 18 years or younger received rapid-COJEC induction chemotherapy, followed by surgical resection when feasible, ASCT with busulfan-melphalan conditioning, radiotherapy, and differentiation therapy with 13-cis-retinoic acid. Eighteen patients were included, with a male-to-female ratio of 2:1 and a median age of 4 years. The adrenal gland was the most common primary site in 55.55% of patients. Bone marrow and bone metastases were present in 72.2% and 44.4% of patients, respectively. Complete response after induction was achieved in 44.4% of patients. Median neutrophil engraftment occurred at 13 days. At a median follow-up of 17 months, 55.5% of patients were alive in remission. Relapse occurred in 50%, with most succumbing to the disease. There was no treatment-related mortality. Two-year event-free and overall survival were 55.3% and 65.6%, respectively. Outcomes were comparable to other resource-limited settings, and the lack of complete response after induction did not adversely affect event-free survival.<\/jats:p>","DOI":"10.1097\/mph.0000000000003215","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T14:00:21Z","timestamp":1781186421000},"page":"e196-e199","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Pediatric High-Risk Neuroblastoma Treated With Autologous Stem Cell Transplant\u2014Experience From a Tertiary Cancer Center in India"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7088-2453","authenticated-orcid":false,"given":"Helie","family":"Raval","sequence":"first","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dale","family":"Montes","sequence":"additional","affiliation":[{"name":"Pediatric Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4872-7159","authenticated-orcid":false,"given":"Maharshi","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chinmay","family":"Doctor","sequence":"additional","affiliation":[{"name":"Pediatric Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsha","family":"Panchal","sequence":"additional","affiliation":[{"name":"Medical Oncology, The Gujarat Cancer and Research Institute, Ahmedabad, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"R1-20260703","first-page":"1302","article-title":"Treatment of high-risk neuroblastoma","volume":"10","author":"Krystal","year":"2023","journal-title":"Children (Basel)"},{"key":"R2-20260703","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.3390\/cancers14112572","article-title":"Autologous stem-cell transplantation for high-risk neuroblastoma: historical and critical review","volume":"14","author":"Mora","year":"2022","journal-title":"Cancers (Basel)"},{"key":"R3-20260703","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/08880018.2020.1850955","article-title":"Survival in patients with high-risk neuroblastoma treated without autologous stem cell transplant or dinutuximab beta","volume":"38","author":"Jain","year":"2021","journal-title":"Pediatr Hematol Oncol"},{"key":"R4-20260703","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4103\/0973-1482.183205","article-title":"Treatment of high-risk neuroblastoma: national protocol results of the Turkish Pediatric Oncology Group","volume":"13","author":"Aksoylar","year":"2017","journal-title":"J Cancer Res Ther"},{"key":"R5-20260703","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1007\/s12098-018-2737-6","article-title":"Treatment of neuroblastoma with a novel delayed intensification chemotherapy","volume":"86","author":"Zhang","year":"2019","journal-title":"Indian J Pediatr"},{"key":"R6-20260703","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1007\/s13312-025-3381-7","article-title":"Post transplant outcomes of high-risk neuroblastoma from a tertiary care unit in India","volume":"62","author":"Bansal","year":"2025","journal-title":"Indian Pediatr"},{"key":"R7-20260703","doi-asserted-by":"crossref","first-page":"e28273","DOI":"10.1002\/pbc.28273","article-title":"Autologous stem cell transplant for high-risk neuroblastoma: achieving cure with low-cost adaptations","volume":"67","author":"Jain","year":"2020","journal-title":"Pediatr Blood Cancer"},{"key":"R10-20260703","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1200\/JCO.2016.72.0177","article-title":"Revisions to the International Neuroblastoma Response Criteria: a consensus statement from the National Cancer Institute Clinical Trials Planning Meeting","volume":"35","author":"Park","year":"2017","journal-title":"J Clin Oncol"},{"key":"R11-20260703","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S1470-2045(17)30070-0","article-title":"Busulfan and melphalan versus CEM as high-dose chemotherapy for high-risk neuroblastoma: HR-NBL1\/SIOPEN randomized trial","volume":"18","author":"Ladenstein","year":"2017","journal-title":"Lancet Oncol"},{"key":"R12-20260703","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1001\/jama.2019.11642","article-title":"Tandem vs single autologous transplant for high-risk neuroblastoma","volume":"322","author":"Park","year":"2019","journal-title":"JAMA"},{"key":"R13-20260703","doi-asserted-by":"crossref","first-page":"453","DOI":"10.3345\/cep.2022.00437","article-title":"Treatment outcomes of high-dose chemotherapy plus stem cell rescue in HR-NB patients in Thailand","volume":"65","author":"Suwannaying","year":"2022","journal-title":"Clin Exp Pediatr"},{"key":"R14-20260703","article-title":"Yan J, Jie L, Jiaxing Y, et al. Analysis of the efficacy of autologous peripheral blood stem cell transplantation in high-risk neuroblastoma. Med Sci. 2022;19:1715-1723"},{"key":"R15-20260703","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1007\/s11523-024-01033-4","article-title":"Survival Benefit of Myeloablative Therapy with Autologous Stem Cell Transplantation in High-Risk Neuroblastoma: A Systematic Literature Review","volume":"19","author":"\u017bebrowska","year":"2024","journal-title":"Target Oncol"},{"key":"R16-20260703","first-page":"490.e1","article-title":"Myeloablative Busulfan\/Melphalan Consolidation following Induction Chemotherapy for Patients with Newly Diagnosed High-Risk Neuroblastoma: Children\u2019s Oncology Group Trial ANBL12P1. Transplantation and Cellular Therapy","volume":"27","author":"Granger","year":"2021"},{"key":"R17-20260703","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s12098-018-2834-6","article-title":"Real world experience of treating neuroblastoma: experience from a tertiary cancer centre in India","volume":"86","author":"Radhakrishnan","year":"2019","journal-title":"Indian J Pediatr"},{"key":"R18-20260703","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1038\/s41409-021-01258-1","article-title":"Long-term follow-up of high-risk neuroblastoma survivors treated with high-dose chemotherapy and stem cell transplantation rescue","volume":"56","author":"Haghiri","year":"2021","journal-title":"Bone Marrow Transplant"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T22:00:23Z","timestamp":1783116023000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000003215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":16,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003215","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]},"assertion":[{"value":"2025-12-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}